Cost‐Effectiveness Analysis of First‐Line Chemotherapy for Metastatic Pancreatic Cancer in Japan
Cancer Medicine · 2025
DOI: 10.1002/cam4.71233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yuriko Sasahara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Yamagata Prefectural Central Hospital, Yamagata, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Cost-Benefit Analysis, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Backgrounds Pancreatic cancer is a highly aggressive disease with limited treatment options. The combination of tegafur, gimeracil, and oteracil (S‐1) has emerged as a promising treatment approach in Japan. However, the economic implications of S‐1 compared to other chemotherapy regimens have not been fully explored.
Methods
This cost‐effectiveness analysis study evaluated the economic position of S‐1 relative to fluorouracil+leucovorin+irinotecan+oxaliplatin (FFX), gemcitabine+Nab‐paclitaxel (GnP), and gemcitabine (GEM) for the treatment of distant metastatic pancreatic cancer in Japan. Incremental cost‐effectiveness ratios were calculated using quality‐adjusted life years (QALYs) as the measure of effectiveness.
Results
S‐1 demonstrated the lowest incremental cost‐effectiveness ratio compared to FFX, GnP, and GEM, indicating that it offers the most value for the cost. The total cost per QALY for S‐1 was significantly lower than the other regimens. Additionally, S‐1 was associated with favourable safety and convenience profiles.
Conclusion
The findings of this study suggest that S‐1 is a cost‐effective and promising treatment option for distant metastatic pancreatic cancer in Japan. Its favourable economic profile, combined with its safety and convenience advantages, makes it a viable choice for patients and healthcare providers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Yamagata Prefectural Central Hospital, Yamagata, Japan.
- Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.
- CRECON Medical Assessment Inc, Tokyo, Japan.
- Cancer Prevention and Cancer Control Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.
- Graduate School of Health Innovation, Kanagawa University of Human Services, Kawasaki, Kanagawa, Japan.
- Department of Genetic Medicine, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
ORCID-Profile: Yuki Takumoto, Hiroto Narimatsu
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sasahara, Y., Takumoto, Y., Murata, T., Akazawa, M., & Narimatsu, H. (2025). Cost‐Effectiveness Analysis of First‐Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. Cancer Medicine. https://doi.org/10.1002/cam4.71233
Vancouver
Sasahara Y, Takumoto Y, Murata T, Akazawa M, Narimatsu H. Cost‐Effectiveness Analysis of First‐Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. Cancer Medicine. 2025. doi:10.1002/cam4.71233
BibTeX
@article{Sasahara2025,
author = {Sasahara, Yuriko and Takumoto, Yuki and Murata, Tatsunori and Akazawa, Manabu and Narimatsu, Hiroto},
title = {Cost‐Effectiveness Analysis of First‐Line Chemotherapy for Metastatic Pancreatic Cancer in Japan},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71233}
}
EUVIMED